From Medscape Oncology

Coverage from the

European Society for Medical Oncology (ESMO) 2019 Annual Meeting

September 27 - October 01, 2019; Barcelona, Spain

September 27 - October 01, 2019 Barcelona, Spain

ESMO 2019 PARP Inhibitors Move Into First-Line for Ovarian Cancer New results with three different drugs in patients with newly diagnosed ovarian cancer "strongly justify moving PARP inhibitors into first-line therapy," says expert.
Medscape Medical News, September 29, 2019
ESMO 2019 One in Two Patients With Metastatic Melanoma Alive After 5 Years With the combination of ipilimumab and nivolumab, 50% of patients are still alive after 5 years, a survival rate remarkably higher than that seen with either agent alone.
Medscape Medical News, September 28, 2019
ESMO 2019 Skipping Radiotherapy After Surgery for Prostate Cancer New results suggest that many men could skip radiotherapy straight after surgery, and be followed with observation and early salvage radiotherapy.
Medscape Medical News, September 28, 2019

Meeting Highlights At A Glance

Top News From ESMO 2019: Slideshow Potentially practice-changing research in metastatic melanoma, as well as lung, ovarian, breast and prostate cancer, featured prominently at ESMO 2019.

Conference News

ESMO 2019 Freezing Desmoid Tumors Halts Progression, May Cure?
Medscape Medical News, October 22, 2019
ESMO 2019 Burnout Common Among Oncologists: What to Do?
Medscape Medical News, October 8, 2019
ESMO 2019 UK Guidelines Offer Coherent Approach to Rare Bladder Cancer
Medscape News UK, October 7, 2019
ESMO 2019 'Landmark' Trial in Prostate Cancer With Mutations
Medscape Medical News, October 4, 2019
ESMO 2019 Cancer Drug Combos Causing Cost-Effectiveness Headaches
Medscape News UK, October 4, 2019
ESMO 2019 'Unprecedented' Results in Biliary Tract Cancer
Medscape Medical News, October 3, 2019
ESMO 2019 Breast Cancer Patients Who Benefit From Chemo: New TAILORx Data
Medscape Medical News, October 2, 2019
ESMO 2019 Disappointment Over Immunotherapy in Mesothelioma
Medscape Medical News, September 30, 2019
ESMO 2019 Immunotherapy Added to CT Might Just Work in Bladder Cancer
Medscape Medical News, September 30, 2019

ESMO 2019 Now With Survival Benefit, CDK4/6 Inhibitors in Breast Cancer
Medscape Medical News, September 30, 2019
ESMO 2019 Immunotherapy Active in Early Stage Triple Negative Breast Cancer
Medscape Medical News, September 29, 2019
ESMO 2019 FLAURA Establishes Osimertinib as 1L Therapy in EGFRm NSCLC
Medscape Medical News, September 29, 2019
ESMO 2019 PARP Inhibitors Move Into First-Line for Ovarian Cancer
Medscape Medical News, September 29, 2019
ESMO 2019 Could All Patients With Advanced NSCLC Go Chemo-Free?
Medscape Medical News, September 28, 2019
ESMO 2019 One in Two Patients With Metastatic Melanoma Alive After 5 Years
Medscape Medical News, September 28, 2019
ESMO 2019 First-line Immunotherapy Still Elusive in Advanced Liver Cancer
Medscape Medical News, September 28, 2019
ESMO 2019 Skipping Radiotherapy After Surgery for Prostate Cancer
Medscape Medical News, September 28, 2019
ESMO 2019 Breast, Lung, & Ovarian Cancer Data to Star at ESMO 2019
Medscape Medical News, September 23, 2019

Medscape Oncology©

Perspectives

Metastatic Breast Cancer Highlights From ESMO 2019
Sibylle Loibl, MD, PhD
NSCLC Highlights From ESMO 2019
Tony Mok, MD
Lung Cancer Therapy Makes Major Advances
Suresh S. Ramalingam, MD
PARP Inhibitors Center Stage for Ovarian Cancer
Susana N. Banerjee, MD, MBBS, MA, PhD, FRCP
What The ESMO Translational Research Award Means to Me
Prof Charles Swanton
KEYNOTE-522: Practice-Changing Potential
Prof Peter Schmid
Why Nurses Need Better Protection From Cytotoxic Chemotherapy Contamination
Matt Fowler
Minimal Residual Disease: The 'Holy Grail' in Adjuvant Chemotherapy
Prof Charles Swanton
ARTISTIC: Sparing Radiotherapy After Prostate Cancer Surgery?
Claire Vale PhD
CheckMate 067: 'Amazing Progress', But Not Resting on Laurels
Prof James Larkin
What Do You Do When Your Patient Starts to Cry?
Bishal Gyawali, MD, PhD
Is There an Ideal Healthcare System for Treating Cancer?
Liam Davenport

Most Popular News from ESMO 2018

Cancer of Unknown Primary: Finding Mutations Alters Therapy Circulating tumor DNA testing for patients with cancer of unknown primary found mutations that are potentially treatable with targeted therapies in 68% of cases, say UK researchers.
Medscape Medical News, Oct 29, 2018
Chemo-Free Therapy for Head and Neck Cancer a Step Closer Patients with head and neck cancer who express relatively high levels of PD-L1 could eventually be treated with immunotherapy rather than chemotherapy, new trial data suggest.
Medscape Medical News, Oct 24, 2018
New Data on RT in Prostate Cancer Are 'Practice Changing' For men with newly diagnosed metastatic prostate cancer who have low metastatic burden, radiotherapy to the prostate provides significant survival benefits, say the STAMPEDE investigators.
Medscape Medical News, Oct 22, 2018

Previous Coverage